Literature DB >> 1657399

Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.

T Crook1, J A Tidy, K H Vousden.   

Abstract

Human papillomavirus (HPV) types 16 and 18 appear to play a role in the development of ano-genital malignancies, whereas HPV 6 and 11 are usually associated with benign lesions. One HPV16 oncoprotein, E6, complexes with and promotes degradation of the cellular tumor suppressor p53. Here we show that E6 proteins of both oncogenic and benign HPV types associate in vitro with p53, but binding by E6 proteins of benign HPV types cannot target p53 for degradation. A C-terminal region of E6 conserved among all HPV types is important for p53 binding. However, N-terminal sequences of E6 conserved only between oncogenic HPV types are necessary to direct p53 degradation. p53 binding by E6 appears necessary but not sufficient for this activity. All E6 proteins tested showed comparable transcriptional trans-activating activity, a property that does not require the ability to bind or direct degradation of p53.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657399     DOI: 10.1016/0092-8674(91)90529-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  167 in total

1.  c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination.

Authors:  R V Sionov; S Coen; Z Goldberg; M Berger; B Bercovich; Y Ben-Neriah; A Ciechanover; Y Haupt
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

2.  Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition.

Authors:  D G Pestov; Z Strezoska; L F Lau
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

3.  Regulation of the 26S proteasome by adenovirus E1A.

Authors:  A S Turnell; R J Grand; C Gorbea; X Zhang; W Wang; J S Mymryk; P H Gallimore
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

Review 4.  Human papillomavirus therapy for the prevention and treatment of cervical cancer.

Authors:  Samir N Khleif
Journal:  Curr Treat Options Oncol       Date:  2003-04

5.  Genetic variations in human papillomavirus and cervical cancer outcomes.

Authors:  Janet S Rader; Shirng-Wern Tsaih; Daniel Fullin; Miriam W Murray; Marissa Iden; Michael T Zimmermann; Michael J Flister
Journal:  Int J Cancer       Date:  2019-01-04       Impact factor: 7.396

6.  Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.

Authors:  S Nakagawa; J M Huibregtse
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  Primary structure of the E6 protein of Micromys minutus papillomavirus and Mastomys natalensis papillomavirus.

Authors:  M Van Ranst; R Tachezy; J Pruss; R D Burk
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

Review 8.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

9.  Differential regulation of human papillomavirus type 6 and 11 early promoters in cultured cells derived from laryngeal papillomas.

Authors:  T P DiLorenzo; B M Steinberg
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  HPV and p53 in cervical cancer.

Authors:  H Y Ngan; M Stanley; S S Liu; H K Ma
Journal:  Genitourin Med       Date:  1994-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.